About CBL

With 30 years in the industry, CBL is recognized as a leader in peptide technology and manufacturing.  CBL’s business areas are GMP manufacturing of:  FMOC and BOC amino acids, solid phase resins, peptide intermediates, API and peptide generics.

CBL is committed to achieving the highest quality and regulatory standards.  This includes leading the  industry by utilizing GMPs for the manufacturing of  peptide starting materials.  Production of peptide clinical and commercial material is offered at all stages of the drug development process in facilities that allow for easy scale up from the early, smaller scale to commercial scale volumes.   To learn more about CBL and view the state-of-the-art, regulatory inspected facilities from FDA and EMA, visit us at www.cblpatras.gr.

  • GR
  • 2019
    On CPhI since
Contact info

Products from CBL

  • Chlorotoxin

    Product Chlorotoxin

    Chlorotoxin is a 36-amino acid peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus) which blocks small-conductance chloride channels. The fact that chlorotoxin binds preferentially to glioma cells has allowed the development of new methods for the treatment and diagnosis of several types of cancer. TM-601 which is the synthetic version of chlorotoxin is under phase II clinical trial. Iodine-131-TM-601 is used to treat malignant glioma. TM-601 is also a candidate for targeting gliomas because it crosses blood-brain and tissue barriers and binds to malignant brain tumor cells without affecting healthy tissue. 
  • Human Epidermal Growth Factor

    Product Human Epidermal Growth Factor

    Human EGF (hEGF) is consisting of 54 amino acids, is an identical molecule to β-urogastrone, a molecule isolated on the basis of its ability to inhibit gastric acid secretion. EGF is structurally homologous to human transforming growth factor-α, and both exert their actions through EGF receptors. This product is used as a mitogen, triggering the cell to commence mitosis, in a variety of cell lines. In tissue cultures, EGF acts to reduce or eliminate the requirement for serum and can be used in conjunction with other media additives and hormones.
  • Human Relaxin-2

    Product Human Relaxin-2

    Relaxin is a protein hormone of about 6000 Da first described in 1926 by Frederick Hisaw. The relaxin-like peptide family belongs in the insulin superfamily. This gene encodes multiple protein isoforms, at least one of which undergoes proteolytic processing. This processing generates relaxin A and B chains that are linked by disulfide bonds to form the mature peptide hormone. This hormone plays a role in the male and female reproductive systems and was initially noted for its role in pregnancy.
  • Liraglutide

    Product Liraglutide

    Liraglutide, sold under the brand name Victoza among others, is a medication used to treat diabetes type 2 and obesity. Liraglutide is not a substitute for insulin and is not for use in people with type 1 diabetes or people with diabetic ketoacidosis. Liraglutide is a long-acting human GLP-1 analogue with 97% amino acid homology to the human endogenous GLP-1. This 97% homology was achieved by substituting arginine for lysine at position 34 of endogenous GLP-1.
  • Octreotide acetate

    Product Octreotide acetate

    Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer.Octreotide is hormone drug that is used to treat some types of cancer. 

  • Semaglutide

    Product Semaglutide

    Semaglutide (trade name Ozempic) is a pharmaceutical drug developed by Danish company Novo Nordisk. Originally developed for the treatment of type 2 diabetes in 2012, it was found in 2017 that it can be used for the treatment of obesity. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient.
  • Teduglutide

    Product Teduglutide

    Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion. In Europe it has been granted orphan drug status and is marketed under the brand Revestive by Nycomed. It was approved by the United States under the name Gattex on 21 December 2012 and also is an orphan drug there. TeduglutFDA approved on December 21, 2012.
  • Tramazoline

    Product Tramazoline

    Tramazoline is a chemical that is used in the form of tramazoline hydrochloride in nasal decongestant preparations.[1] It is an α-adrenergic receptor agonist that inhibits secretion of nasal mucus. It was patented in 1961 and came into medical use in 1962.

CBL Resources

  • News FDA & EMA inspected

    CBL, the “Peptide Innovators” was recently inspected both by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Approvals were received from both agencies for the API manufacturing of octreotide.